

:  
BEP  
1

• • • •

=Abstract=

A case of endodermal sinus tumor of ovary;—Complete remission  
& full-term delivery after conservative surgery and BEP therapy

Woo-Gyeong Kim, M.D., Kyung-Bok Lee, M.D., Moon-Su Sung, M.D.,  
Ki-Tae Kim, M.D., Hyun-Chan Kim, M.D.

*Department of Obstetrics and Gynecology, Pusan Paik Hospital, College of Medicine, Inje University*

The endodermal sinus tumor of ovary is a rare, malignant germ cell tumor. It principally affects children and young adults. Earlier reports before combination chemotherapy described it was fatal and the prognosis was poor. The advances in treatment of endodermal sinus tumor have been achieved with the development of combination chemotherapy with monitoring tumor marker, serum AFP. The authors experienced a case of endodermal sinus tumor of ovary which showed complete remission following primary conservative surgery and three courses of combination chemotherapy(BEP) with normal full-term spontaneous delivery. With the case report, a brief review was made.

**Key words** : Endodermal sinus tumor, Complete remission, NFSD

I. .

, 20 , : OO, 24 , .  
: 1

. 가 : .  
AFP : 7

. 24 : 15 , 28  
, 4

3 , . 1995 5 24  
BEP .  
, : Para 0-0-0-0,  
: 1995 6 12 , 1

가  
 : 48kg, 100/60  
 mmHg, 110/min, 38.5

7.5gm%, 22%,  
 6,700/mm3, 470,000/mm3  
 X-  
 110  
 -FP: 2,098 ng/ml ( :<20  
 ng/ml), CA 125: 600 U/ml ( :<35 U/ml) 가  
 , -hCG: 0.01 mIU/ml ( :<10  
 mIU/ml), CEA: 2.9 ng/ml ( : <5 ng/ml)

: 16x10  
 cm 가

(Fig. 1).  
 (Resistive index)  
 0.2  
 : 4

1,000cc 가 ,  
 vesicular tumor cell

Douglas  
 ,  
 가

Fig 1. Transabdominal Sonography (before operation)  
 A large mixed ecogenic mass attached to the uterine  
 fundus with large amount of ascites

Douglas  
 : 15.0 × 11.0 ×  
 7.0 cm 644.0 gm

Fig 2. Reticular pattern of a endodermal sinus tumor  
 with variably sized cystic space lined by  
 attenuated epithelial cells(H&E x100) and well  
 formed Schiller-Duval bodies (inset, H&E x200)

Table 1. Modified BEP regimen

Bleomycin	30mg iv	on day5	q 3 wks x 3
Etoposide	100mg/m2	on day1,2,3,4,5	q 3 wks x 3
Cisplatin	20mg/m2	on day1,2,3,4,5	q 3 wks x 3

Fig 3. Serum -FP titer follow up after primary surgery and 3 course of BEP chemotherapy

Shiller-Duval body가 (Fig. 2).  
 : 1995 6 19  
 IC 8 , William 25)  
 BEP cisplatin 20 mg/m2  
 (day 1, 2, 3, 4, 5), bleomycin 30 mg (day 5), etoposide  
 100 mg/m2 (day 1, 2, 3, 4, 5) 1  
 , 3 3  
 (Table 1).

, 3 , 3  
 -FP(Fig. 1  
 3) 96 1 5  
 1997, 5  
 7 28 7 ,  
 7  
 1998  
 3 21 2.99 kg  
 1998 6  
 98 11 18  
 , -FP: 1.84 ng/ml, CA 125: 7.78 U/ml,  
 -HCG: 0.01 mIU/ml

(extraembryonic)  
 “yolk sac tumor”  
 1).  
 , 1% 2).  
 14 45 , 40  
 , 16  
 18 , 1/3  
 3).  
 75% 가 ,  
 74 % ,  
 45).  
 10% ,  
 (1  
 :71%, 2 :6%, 3 :23%)6).  
 1  
 , 38.5OC  
 -FP  
 5), alpha-1-antitrypsin(AAT)  
 -FP  
 -FP  
 78).  
 -FP 2,098 ng/ml ,  
 1 BEP  
 9).  
 ,

reticular, festoon or pseudopapillary, polyvesicular vitelline solid pattern, reticular pattern 가 7), flattened tubular structure, paraaminosalicylic-positive globule flattened 가 papillary structure, Schiller-Duval body 75%, eosinophilic, periodic acid-Schiff (PAS), diastase-resistance hyaline globule reticular, festoon pattern, extracellular hyaline PAS-positive material reticular, solid area 101), reticular pattern Shiller-Duval body가 . , , 가 312), , , 20 , 24 , 3 BEP , 13), , 1 84%가 , 93% 7). 1970

#### VAC

1417). VAC(Vincristine, Actinomycin-D, Cyclophosphamide) alli-son 18) 68%, Gershenson 19) 69% 60 70% 2 . VBP(Vincristine, Bleomycin, Cisplatin) 가 ,

#### VAC

#### 가

2023). vinblastine etoposide BEP(Bleomycin, Etoposide, Cisplatin), VBP 1 3-4 22,25,28). BEP 가 2932) 가 . 가 , 20 24 3 BEP , 13). . -References-

1. Berek JS, Hacker NF: Ovarian and fallopian tubes. In: Haskell CM,ed : Cancer Treatment. 4th ed. Philadelphia: WB Saunder, 1995.
2. Kurman RJ, Norris HJ: Malignant germ cell tumor of the ovary. Hum Pathol 1977; 8:551-64.
3. Slayton RE: Management of germ cell and stromal tumors of the ovary. Semin Oncol 1984;11:299-313.
4. Gershenson DM, Morris M, Canger A et al: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715-20.

5. Wilkinson EJ, Friedrich EG, Hosty TA: Alpha-fetoprotein and endodermal sinus tumor of the ovary. *Am J Obstet Gynecol* 1973; 116:711-4.
6. Cangir A, Smith J, Van Eys J: Improved prognosis in children with ovarian cancers followed modified VAC(vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy. *Cancer* 1978;42:1234-8.
7. Kurman RJ, Norris HJ: Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. *Cancer* 1976;38:2404-19.
8. Talerman A, Haije WG, Baggerman L: Serum alpha-fetoprotein(AFP) in patients with germ cell tumors of the gonads and extragonadal sites: correlation between endodermal sinus (yolk sac) tumors and raised serum AFP. *Cancer* 1980;46:380-5.
9. Gompel C, Silverberg SG: The ovary, Zaloudex C, 4th ed, Pathology in gynecology and Obstetrics, Philadelphia, J.B.Lippincott 1994:382
10. Langley FA, Govan ADT, Anderson MC et al: Yolk sac and allied tumours of the ovary. *Histopathology* 1981;5:389-401.
11. Ulbright TM, Roth LM, Brodhecker CA: Yolk sac differentiation in germ cell tumors: A morphologic study of 50 cases with emphasis on hepatic, enteric, and parietal yolk sac features. *Am J Surg Pathol* 1986;10:151-64.
12. Thomas GM, Dembo AJ, Hacker NF et al: Current therapy for dysgerminoma of the ovary. *Obstet Gynecol* 1987;70:268-75.
13. Williams SD, Gershenson DM, Horowitz CJ et al.: Ovarian Germ-cell Tumors, Hoskins WJ, Perez CA, Young RC: Principles and Practice of Gynecologic Oncology 2nd ed. Philadelphia Lippincott-Raven 1997;987-1001
14. Malkasian GD, Webb MJ, Jorgensen EO: Observation on chemotherapy of granulosa cell carcinoma and malignant ovarian teratomas. *Obstet Gynecol* 1974;44:885-8.
15. Smith JP, Rutledge FN: Advances in chemotherapy for gynecologic cancer. *Cancer* 1975;36:669-74.
16. Cangir, Smith J, Van Eys J: Improved prognosis in children with ovarian cancer following modified VAC chemotherapy. *Cancer* 1978;42:1234-8.
17. Curry SL, Smith JP, Gallagher HS: Malignant teratoma of the ovary: Prognostic factor and treatment. *Am J Obstet Gynecol* 1978;131:845-94.
18. Gallion H, Van Nagell JR, Pall BF: Therapy of endodermal sinus tumors of the ovary, *Am J Obstet Gynecol* 1979;135:447
19. Gershenson DM, Junco GD, Herson J et al: Endodermal sinus tumor of the ovary: the M.D. Anderson Experience. *Obstet Gynecol* 1983;61:194.
20. Slayton RE, Park RC, Silverberg SG et al: Vincristine, dactinomycin and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncology Group study. *Cancer* 1985;56(2):243-8.
21. Taylor MH, DePetrillo AD, Turner AR: Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. *Cancer* 1985;56(6):1341-9.
22. Williams SD, Blessing JA, Moore DH, et al: Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors. *Ann Intern Med* 1989;111:22
23. Schwartz PE, Chambers SK, Chambers JT et al: Ovarian germ cell malignancies: the Yale University experience. *Gynecol Oncol* 1992;45:26.
24. Peckham MJ, Barret A, Liew KH, et al: The treatment of metastatic germ cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). *Br J Cancer* 1983;47:613-9.
25. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. *N England J Med* 1987;316:1435-40.
26. Smith EB, Clarke-Pearson DL, Creasman WT: A VP 16-213-and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. *Am J Obstet Gynecol* 1984;150:927-31.
27. Gershenson DM, Morris M, Cangir A et al: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide and cisplatin. *J Clin Oncol* 1990;8:715-20.
28. Williams SD, Blessing JA, Hatch K et al: Chemotherapy of advanced ovarian dysgerminoma: trial of the Gynecologic Oncology Group. *J Clin Oncol* 1991;9:1950.
29. : BEP  
1993;36:3358-65.
30. : VAC BEP  
1994;37:2290-6.
31. :  
1995;38:1296-302.
32. BEP  
1997;40:2581-84.